Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients

The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases

The purpose of this study is to determine whether the new RIC regimen, containing of low dose of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged and/or intolerable patients with hematologic malignant disease, who undergoes allogenic stem cell transplantation.

Inclusion Criteria:

• diagnosed of hematologic malignant disease
• will undergo HLA matced HSCT
• age >=55years
• <55year and intolerable to standard myeloablative conditioning

Exclusion Criteria:

• KPS status <70
• cardiac EF<50%
• creatine clearance <50 ml/min
• ALT more than 10 times of upper normal limit